US 12,012,440 B2
Compositions and methods for treatment of fungal infections
Michael E. Selsted, Pasadena, CA (US); Dat Q. Tran, Alhambra, CA (US); Justin B. Schaal, Orange, CA (US); and Virginia Basso, West Covina, CA (US)
Assigned to The University of Southern California, Davis, CA (US)
Filed by THE UNIVERSITY OF SOUTHERN CALIFORNIA, Los Angeles, CA (US)
Filed on Jun. 25, 2021, as Appl. No. 17/358,828.
Claims priority of provisional application 63/044,943, filed on Jun. 26, 2020.
Prior Publication US 2021/0403523 A1, Dec. 30, 2021
Int. Cl. C07K 14/47 (2006.01); A61K 38/00 (2006.01); A61P 31/10 (2006.01); C07K 7/64 (2006.01)
CPC C07K 14/4723 (2013.01) 11 Claims
 
1. A cyclic peptide consisting of 14 amino acids and having the following structure:

OG Complex Work Unit Chemistry
wherein AA1, AA2, AA13, and AA14 are amino acids, AA3 and AA12 are cysteines joined by a disulfide bond, AA5 and AA10 are cysteines joined by a disulfide bond, AA4 is serine or a hydrophobic amino acid, AA9 and AA11 are a hydrophobic amino acids, two of AA6, AA7, and AA8 are arginine, wherein a β turn segment of the cyclic peptide defined by AA6, AA7, AA8, and AA9 does not include more than two adjacent arginines, and wherein the cyclic peptide comprises five or more arginine residues that provide a positively charged content of at least about 36% at physiological pH, wherein the cyclic peptide has an antifungal activity.